IFNG and non-small cell lung carcinoma: In NSCLC and melanoma, patients with a high level of mRNA expression of IFNG (the gene that encodes IFN-γ) exhibit longer progression-free and overall survival and have higher disease control rates with anti-PD-1 therapies [47].